BUY MBP ABIRATERONE ACETATE ABIRATAS 500 60 TAB BEST PRICE ONLINE IN NIGERIA LAGOS ABUJA KANO AND PORTHARCOURT AT MYBIGPHARMACY.COM

Description

Dear friend, this medication requires a prescription or medical license before it can be delivered to you. kindly ensure that you provide us with a reliable contact information at checkout, mybigpharmacy team will be in touch with you to obtain required document before your order is confirmed thank you for trusting mybig pharmacy with your health. Abiraterone acetate is an oral hormonal anticancer medicine used in the management of advanced and metastatic prostate cancer. Prostate cancer growth is driven by male hormones known as androgens, particularly testosterone. While traditional hormone treatments reduce testosterone production from the testes, abiraterone works more comprehensively by blocking an enzyme called CYP17. This enzyme is involved in androgen production not only in the testes, but also in the adrenal glands and within the tumour itself. By inhibiting this pathway, abiraterone significantly lowers androgen levels throughout the body, which helps slow disease progression and improve outcomes.

Because CYP17 inhibition also reduces the production of cortisol, the body may respond by increasing mineralocorticoid hormones. This can lead to side effects such as fluid retention, high blood pressure, and low potassium levels. For this reason, abiraterone must always be taken together with a corticosteroid, usually prednisolone or prednisone. The steroid replaces the missing cortisol and suppresses excess mineralocorticoid production, helping to maintain hormonal balance and reduce complications. It is essential that the steroid is taken exactly as prescribed and not stopped abruptly, as sudden withdrawal can result in adrenal insufficiency.

Abiraterone is taken once daily, usually as four tablets taken together, unless otherwise directed by the prescriber. It must be taken on an empty stomach. The patient should not eat for at least two hours before taking the dose and should wait at least one hour after taking it before eating. This is clinically important because food significantly increases the absorption of abiraterone, which can result in unpredictable blood levels and a higher risk of toxicity. The tablets should be swallowed whole with water and must not be crushed, chewed, or broken.

Adherence to dosing instructions is critical. If a dose is missed, the patient should skip that dose and take the next dose at the usual time the following day. Double dosing must be avoided. If more than one dose is missed, the patient should contact their healthcare provider for further advice.

Abiraterone is generally well tolerated, but patients should be counselled on both common and serious adverse effects. Common side effects include fatigue, weakness, hot flushes, joint or muscle pain, mild gastrointestinal upset, peripheral oedema, and increases in blood pressure. These effects are often manageable but should be reported during follow-up appointments.

More serious adverse effects relate to liver function, electrolyte imbalance, and cardiovascular status. Abiraterone can cause elevations in liver enzymes and, in rare cases, severe liver injury. Patients should be advised to report symptoms such as yellowing of the skin or eyes, dark urine, severe nausea, vomiting, or upper abdominal pain. Regular liver function tests are mandatory, particularly during the early months of treatment.

Low potassium levels may present as muscle weakness, cramps, palpitations, or abnormal heart rhythms. Fluid retention may cause rapid weight gain, swelling of the legs or ankles, or shortness of breath. These effects require prompt medical assessment. Blood pressure should be monitored regularly, especially in patients with a history of hypertension or cardiovascular disease.

Patients with pre-existing heart disease, heart failure, arrhythmias, or poorly controlled hypertension require close monitoring while on abiraterone. They should be advised to seek urgent medical attention if they experience chest pain, sudden breathlessness, fainting, or severe dizziness.

Abiraterone is metabolised in the liver and can interact with other medicines. Patients should inform their pharmacist or doctor about all medicines they are taking, including prescription medicines, over-the-counter products, vitamins, and herbal supplements. New medicines should not be started without professional advice, as interactions may affect treatment safety or effectiveness.

From a safety and handling perspective, abiraterone tablets should not be handled by pregnant women or women who may become pregnant unless gloves are worn, due to the risk of harm to an unborn baby. Hands should be washed after handling the tablets, and the medicine should be stored in its original container, out of reach of children.

Patients should be advised not to stop abiraterone or the accompanying steroid without medical instruction, even if they feel well or believe the treatment is no longer needed. Continuous therapy and regular monitoring are essential components of safe and effective treatment.

In summary, abiraterone acetate is a potent and targeted hormonal therapy for prostate cancer that requires strict adherence to dosing instructions, concurrent steroid use, and ongoing clinical monitoring. When taken correctly and monitored appropriately, it plays a significant role in controlling disease progression and maintaining quality of life. Patients should be encouraged to ask questions, attend all blood test appointments, and promptly report any concerning symptoms to their healthcare team.